NONRACEMIC MIXTURES AND USES THEREOF
    1.
    发明公开

    公开(公告)号:US20230285356A1

    公开(公告)日:2023-09-14

    申请号:US17977920

    申请日:2022-10-31

    CPC classification number: A61K31/40 A61P25/24

    Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.

    NONRACEMIC MIXTURES AND USES THEREOF

    公开(公告)号:US20210315860A1

    公开(公告)日:2021-10-14

    申请号:US17097799

    申请日:2020-11-13

    Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.

    Solid Forms Comprising(-)-O-Desmethylvenlafaxine And Uses Thereof
    4.
    发明申请
    Solid Forms Comprising(-)-O-Desmethylvenlafaxine And Uses Thereof 审中-公开
    ( - ) - O-去甲基文拉法辛的固体形式及其用途

    公开(公告)号:US20160355457A1

    公开(公告)日:2016-12-08

    申请号:US15164394

    申请日:2016-05-25

    Abstract: Solid forms comprising a compound useful in the treatment, prevention and management of various conditions and diseases are provided herein. In particular, the invention provides solid forms comprising (−)-O-desmethylvenlafaxine, including salts thereof, having utility for the treatment, prevention and management of conditions and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

    Abstract translation: 本文提供了包含可用于治疗,预防和治疗各种病症和疾病的化合物的固体形式。 特别地,本发明提供了包含( - ) - O-去甲基文拉法辛(包括其盐)的固体形式,其可用于治疗,预防和治疗病症和病症,包括但不限于情感障碍如抑郁症,双相和躁狂症 失调,注意力缺陷障碍,具有多动症的注意力缺陷障碍,帕金森病,癫痫,脑功能障碍,肥胖和体重增加,失禁,痴呆和相关疾病。

    NONRACEMIC MIXTURES AND USES THEREOF
    8.
    发明申请

    公开(公告)号:US20190314331A1

    公开(公告)日:2019-10-17

    申请号:US16452880

    申请日:2019-06-26

    Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.

    Nonracemic mixtures and uses thereof

    公开(公告)号:US10369134B2

    公开(公告)日:2019-08-06

    申请号:US16209412

    申请日:2018-12-04

    Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.

Patent Agency Ranking